编辑丨于靖
近日,Compass Therapeutics公布了其VEGF/DLL4(CTX-009)双特异抗体联合紫杉醇在治疗胆道癌(BTC)的2期临床中期研究成果,结果表明该双抗药物安全性良好,在24名患者中有10位病人平均治疗6个月后得到了客观缓解,ORR为42%(10/24),算不上惊艳,...查看全文
usbiostock2018-08-03 09:49
$OncoMed Pharmaceuticals, Inc. (OMED)$ 1. Navicixizumab单药治疗实体瘤临床1a期试验一线数据预计:2018年第4季度;2. Etigilimab单药治疗进展性/转移性实体瘤临床1a期试验一线数据预计:2018年第4季度;3. 现金:$79.9M。查看全文
$Oncomed制药(OMED)$ 425 - Prospectuses and communications, business combinations Filed: 2019-02-12 AccNo: 0000950103-19-001868 Size: 15 MB 网页链接
$Oncomed制药(OMED)$ 425 - Prospectuses and communications, business combinations Filed: 2019-02-11 AccNo: 0001193125-19-033932 Size: 20 MB 网页链接
$Oncomed制药(OMED)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-08 AccNo: 0001104659-19-006816 Size: 70 KB 网页链接
$Oncomed制药(OMED)$ 8-K - Current report Filed: 2019-01-28 AccNo: 0001193125-19-018841 Size: 16 KBItem 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 网页链接
$Oncomed制药(OMED)$ 8-K - Current report Filed: 2019-01-28 AccNo: 0001193125-19-018841 Size: 16 KBItem 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 网页链接
$Oncomed制药(OMED)$ 425 - Prospectuses and communications, business combinations Filed: 2019-01-07 AccNo: 0000950103-19-000276 Size: 16 MB 网页链接
$Oncomed制药(OMED)$ 内部交易: 2018-12-24,See Remarks,Gurney Austin ,卖出,11117普通股, $0.60
$Oncomed制药(OMED)$ SC 13D - General statement of acquisition of beneficial ownership Filed: 2018-12-17 AccNo: 0000950103-18-014700 Size: 94 KB 网页链接
$Oncomed制药(OMED)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-12-21 AccNo: 0001193125-18-355177 Size: 96 KB 网页链接
$OncoMed Pharmaceuticals, Inc.(OMED)$ SC 13D - General statement of acquisition of beneficial ownership Filed: 2018-12-17 AccNo: 0000950103-18-014700 Size: 94 KB 网页链接